Rocket Pharmaceuticals(US:RCKT) Prnewswireยท2025-07-23 20:06Group 1 - A class action has been filed on behalf of investors who acquired Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 7, 2025, and May 26, 2025 [1] - The allegations state that Rocket Pharmaceuticals misled investors regarding the viability and efficacy of its RP-A501 drug, particularly concerning the Phase 2 pivotal trial for Danon disease [2] - Following the announcement of a Serious Adverse Event (SAE) related to the trial, Rocket's stock price dropped significantly from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025 [3] Group 2 - The complaint highlights that the company created a false impression of having reliable information about the trial's timeline and safety, which was contradicted by the reality of the situation [2] - The FDA placed the trial on hold due to the introduction of a novel immunomodulatory agent, which was part of an amended protocol that led to a patient's death [2] - Shareholders interested in participating in the class action can contact Robbins LLP, with the option to serve as lead plaintiff or remain an absent class member [4]